Przejdź do zawartości
Merck

SBPV04

Sigma-Aldrich

BCRP Human Vesicular Transport Kit

membrane based kit for Human BCRP Vesicular Transport Assays

Synonim(y):

ABCG2, Breast Cancer Resistance Protein

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Kod UNSPSC:
12352200

rekombinowane

expressed in human cells

numer dostępu UniProt

Warunki transportu

dry ice

temp. przechowywania

−70°C

informacje o genach

human ... ABCG2(9429)

Opis ogólny

SOLVO Biotechnology offers ready-to-use assay kits for efflux and uptake transporters. SOLVO′s PREDIVEZ Vesicular Transport Assay Kits are suitable for efflux transporter inhibition studies. The kits are designed to test the inhibitory effect of one or more test compounds on the vesicular transport of a probe substrate. In most cases a fluorescent probe substrate is included. Kits contain all reagents and solutions necessary to conduct the drug-transporter interaction assay of need.

Zastosowanie

The PREDIVEZTM Vesicular Transport Kit is a simple and powerful tool to investigate drug transporter interactions. It provides information on any interaction between the ABC transporter and the drug candidate that would affect the transport of the fluorescent or radiolabeled or cold.

PREDIVEZTM vesicular transport kits are available in three sizes 3, 6 or 9 compound sizes. The kits contain the sufficient amount of reagents and membrane preparations needed for the testing of 3 compounds per 96-well plate. Each kit is accompanied by a CD that includes the assay protocol, an Excel spreadsheet with a data processing template, SDS and the inhibition curves with reference compounds.

Postać fizyczna

Supplied as frozen membrane vesicles, containing 5 mg/ml membrane protein, labeled with volume, catalog number (transporter), date of production, protocols and necessary reagents sufficent for the analysis of 3, 6, or 9 test compounds

Informacje prawne

Distributed for SOLVO Biotechnology, Inc.
This page may contain text that has been machine translated.

produkt powiązany

Piktogramy

Health hazardCorrosion

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

Klasyfikacja zagrożeń

Carc. 2 - Eye Dam. 1 - Lact. - Met. Corr. 1 - Repr. 1A - Skin Corr. 1B

Kod klasy składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Márton Jani et al.
Journal of pharmaceutical sciences, 100(1), 94-97 (2010-06-25)
Ivermectin is an antiparasitic drug frequently administered to humans. It has a limited brain exposure that is attributed to the efflux activity of ABCB1/Abcb1. ABCG2/Abcg2 is also a major transporter present in most pharmacologically important barriers. However, interaction of ivermectin
Albert Mennone et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(10), 1673-1678 (2010-07-06)
Breast cancer resistance protein (Bcrp) is a member of the ATP-binding cassette membrane transporter family, which is expressed apically in liver, kidney, and intestine epithelium. Recent reports suggest that in addition to xenobiotics, porphyrins, and food toxins, Bcrp can also
Márton Jani et al.
Biological & pharmaceutical bulletin, 32(3), 497-499 (2009-03-03)
The pharmacokinetics of sulfasalazine, an anti-inflammatory drug is influenced by ATP-binding cassette G2 (ABCG2) (breast cancer resistance protein (BCRP), mitoxantrone resistance protein (MXR)) both in vitro and clinically. Due to its low passive permeability, the intracellular concentration of sulfasalazine is
E Kis et al.
Annals of the rheumatic diseases, 68(7), 1201-1207 (2008-04-10)
Earlier publications have suggested a possible role for the efflux transporter breast cancer resistance protein (BCRP) in acquired resistance to disease-modifying antirheumatic drugs (DMARDs) such as leflunomide and its metabolite A771726 (teriflunomide). However, there is no direct evidence that BCRP
Kumie Kage et al.
International journal of cancer, 97(5), 626-630 (2002-01-25)
Breast cancer resistance protein (BCRP) is a half-molecule ABC transporter highly expressed in mitoxantrone-resistant cells. In our study we established PA317 transfectants expressing Myc-tagged BCRP (MycBCRP) or HA-tagged BCRP (HABCRP). The exogenous BCRP protein migrated as a 70-kDa protein in

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej